Show simple item record

dc.contributor.authorvan de Leemput, Joyce
dc.contributor.authorHan, Zhe
dc.date.accessioned2021-06-21T14:55:03Z
dc.date.available2021-06-21T14:55:03Z
dc.date.issued2021-06-14
dc.identifier.urihttp://hdl.handle.net/10713/16057
dc.description.abstractSARS-CoV-2 causes the COVID-19 pandemic responsible for millions of deaths globally. Even with effective vaccines, the SARS-CoV-2 virus will likely maintain a hold in the human population through gaps in efficacy and vaccination and arising new strains. Therefore, understanding how SARS-Cov-2 causes such wide-spread tissue damage and developing targeted pharmacological treatments will be critical in fighting this virus and preparing for future outbreaks. Herein, we summarize the progress made thus far by using in vitro or in vivo models to investigate individual SARS-CoV-2 proteins and their pathogenic mechanisms. We grouped the SARS-CoV-2 proteins into three categories: host-entry, self-acting and host-interacting. This review focuses on the self-acting and host-interacting SARS-CoV-2 proteins and summarizes current knowledge on how these proteins promote virus replication and disrupt host systems, as well as drugs that target these virus- and interacting host proteins. Many of these drugs are currently in clinical trials for the treatment of COVID-19. Future coronavirus outbreaks will mostly likely be caused by new virus strains that evade the vaccines through mutations in host-entry proteins. Therefore, study of individual self-acting and host-interacting SARS-CoV-2 proteins for targeted therapeutic interventions is not only essential for fighting COVID-19, but also valuable against future coronavirus outbreaks.en_US
dc.description.urihttps://doi.org/10.1128/MCB.00185-21en_US
dc.language.isoenen_US
dc.publisherAmerican Society for Microbiologyen_US
dc.relation.ispartofMolecular and Cellular Biologyen_US
dc.subjecthost-interacting proteinsen_US
dc.subjectself-acting proteinsen_US
dc.subjecttargeted drug developmenten_US
dc.subject.meshCOVID-19en_US
dc.subject.meshSARS-CoV-2--pathogenicityen_US
dc.titleUnderstanding individual SARS-CoV-2 proteins for targeted drug development against COVID-19en_US
dc.typeArticleen_US
dc.identifier.doi10.1128/MCB.00185-21
dc.identifier.pmid34124934
dc.source.beginpageMCB0018521
dc.source.endpage
dc.source.countryUnited States


This item appears in the following Collection(s)

Show simple item record